No Data
The Analyst Landscape: 7 Takes On AnaptysBio
In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates their rec
Wedbush Reiterates Outperform on AnaptysBio, Maintains $34 Price Target
Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:ANAB) with a Outperform and maintains $34 price target.
AnaptysBio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 34.28% Wedbush → $34 Reiterates Outperform → Outperform 04/16/2024 85.62% Leerink Partners → $4
Wedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Buy Rating Affirmed for AnaptysBio Amidst Promising Pipeline and Strategic Financial Positioning
AnaptysBio GAAP EPS of -$1.64 Misses by $0.04